WO2004028521A3 - Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders - Google Patents

Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders Download PDF

Info

Publication number
WO2004028521A3
WO2004028521A3 PCT/EP2003/010579 EP0310579W WO2004028521A3 WO 2004028521 A3 WO2004028521 A3 WO 2004028521A3 EP 0310579 W EP0310579 W EP 0310579W WO 2004028521 A3 WO2004028521 A3 WO 2004028521A3
Authority
WO
WIPO (PCT)
Prior art keywords
sphingosine
treatment
receptor agonists
phosphate receptor
demyelinating disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/010579
Other languages
French (fr)
Other versions
WO2004028521A2 (en
Inventor
Carolyn Ann Foster
Peter C Hiestand
Paul William Glue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/528,688 priority Critical patent/US20060046979A1/en
Priority to CNA038227088A priority patent/CN1708293A/en
Priority to BR0314760-6A priority patent/BR0314760A/en
Priority to JP2005509665A priority patent/JP4509028B2/en
Priority to CA2499622A priority patent/CA2499622C/en
Priority to AU2003266404A priority patent/AU2003266404B2/en
Priority to MXPA05003254A priority patent/MXPA05003254A/en
Priority to KR1020117007334A priority patent/KR101188943B1/en
Priority to EP03798176A priority patent/EP1575576A2/en
Priority to KR1020097024162A priority patent/KR101095807B1/en
Priority to NZ538961A priority patent/NZ538961A/en
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2004028521A2 publication Critical patent/WO2004028521A2/en
Publication of WO2004028521A3 publication Critical patent/WO2004028521A3/en
Priority to ZA2005/02032A priority patent/ZA200502032B/en
Anticipated expiration legal-status Critical
Priority to NO20051934A priority patent/NO334908B1/en
Priority to US12/512,410 priority patent/US20090324542A1/en
Priority to US13/464,294 priority patent/US20120225031A1/en
Priority to NO20131569A priority patent/NO20131569L/en
Priority to US14/217,513 priority patent/US20140271541A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.
PCT/EP2003/010579 2002-09-24 2003-09-23 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders Ceased WO2004028521A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
NZ538961A NZ538961A (en) 2002-09-24 2003-09-23 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
BR0314760-6A BR0314760A (en) 2002-09-24 2003-09-23 Organic compounds
JP2005509665A JP4509028B2 (en) 2002-09-24 2003-09-23 Organic compounds
CA2499622A CA2499622C (en) 2002-09-24 2003-09-23 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
AU2003266404A AU2003266404B2 (en) 2002-09-24 2003-09-23 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
MXPA05003254A MXPA05003254A (en) 2002-09-24 2003-09-23 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders.
KR1020117007334A KR101188943B1 (en) 2002-09-24 2003-09-23 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
EP03798176A EP1575576A2 (en) 2002-09-24 2003-09-23 Organic compounds
KR1020097024162A KR101095807B1 (en) 2002-09-24 2003-09-23 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
US10/528,688 US20060046979A1 (en) 2002-09-24 2003-09-23 Organic compounds
CNA038227088A CN1708293A (en) 2002-09-24 2003-09-23 Sphingosine-1-phosphate receptor agonists for the treatment of demyelinating diseases
ZA2005/02032A ZA200502032B (en) 2002-09-24 2005-03-10 Organic compounds
NO20051934A NO334908B1 (en) 2002-09-24 2005-04-20 Pharmaceutical preparation for the treatment of optic neuritis and its use.
US12/512,410 US20090324542A1 (en) 2002-09-24 2009-07-30 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
US13/464,294 US20120225031A1 (en) 2002-09-24 2012-05-04 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
NO20131569A NO20131569L (en) 2002-09-24 2013-11-27 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
US14/217,513 US20140271541A1 (en) 2002-09-24 2014-03-18 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41317202P 2002-09-24 2002-09-24
US60/413,172 2002-09-24
US48513203P 2003-07-07 2003-07-07
US60/485,132 2003-07-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/528,688 A-371-Of-International US20060046979A1 (en) 2002-09-24 2003-09-23 Organic compounds
US12/512,410 Continuation US20090324542A1 (en) 2002-09-24 2009-07-30 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders

Publications (2)

Publication Number Publication Date
WO2004028521A2 WO2004028521A2 (en) 2004-04-08
WO2004028521A3 true WO2004028521A3 (en) 2004-05-27

Family

ID=32045240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/010579 Ceased WO2004028521A2 (en) 2002-09-24 2003-09-23 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders

Country Status (16)

Country Link
US (4) US20060046979A1 (en)
EP (3) EP1575576A2 (en)
JP (2) JP4509028B2 (en)
KR (4) KR101188943B1 (en)
CN (3) CN1708293A (en)
AU (3) AU2003266404B2 (en)
BR (1) BR0314760A (en)
CA (1) CA2499622C (en)
MX (1) MXPA05003254A (en)
NO (2) NO334908B1 (en)
NZ (2) NZ564626A (en)
PL (2) PL408347A1 (en)
RU (3) RU2391094C2 (en)
TW (2) TWI376363B (en)
WO (1) WO2004028521A2 (en)
ZA (1) ZA200502032B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (en) 2001-11-21 2003-05-21 Univ Roma IMMUNOREGULATORY COMPOUNDS.
DK1471054T3 (en) 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Amino alcohol derivative or phosphonic acid derivative and medical composition containing them
AU2003233119A1 (en) 2002-05-08 2003-11-11 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005058348A1 (en) * 2003-12-11 2005-06-30 Axys Pharmaceuticals, Inc. Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
AU2005237254B2 (en) * 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP1806338B1 (en) * 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
PL1650186T3 (en) * 2004-10-22 2008-11-28 Bioprojet Soc Civ Novel dicarboxylic acid derivatives
KR20070085465A (en) * 2004-11-29 2007-08-27 노파르티스 아게 Dosage of S1 receptor agonist
WO2006063033A2 (en) 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
PT1828160E (en) 2004-12-21 2012-01-05 Merck Serono Sa Sulfonyl amino cyclic derivatives and use thereof as mmp inhibitors
RS51957B (en) 2005-01-31 2012-02-29 Merck Serono Sa. N-HYDROXIAMIDE DERIVATIVES AND THEIR USE
US7754703B2 (en) 2005-02-14 2010-07-13 University Of Virginia Patent Foundation Cycloalkane-containing sphingosine 1-phosphate agonists
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
EA013816B1 (en) * 2005-09-01 2010-08-30 Арес Трейдинг С.А. Treatment of optic neurotis
ES2529724T3 (en) * 2005-09-09 2015-02-25 Novartis Ag Treatment of autoimmune diseases
PL1932522T3 (en) * 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient
CA2633167A1 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
JP2009528274A (en) 2006-01-27 2009-08-06 ユニバーシティ オブ バージニア パテント ファンデーション Treatment of neuropathic pain
TWI389683B (en) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
JP2009526073A (en) 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション Bicyclic sphingosine-1-phosphate receptor analogs
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
JP5140593B2 (en) * 2006-08-08 2013-02-06 杏林製薬株式会社 Amino alcohol derivatives and immunosuppressants containing them as active ingredients
CA2659598A1 (en) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
AU2012216651B2 (en) * 2006-08-17 2013-08-01 University Of Chicago Treatment of inflammatory diseases
HRP20121034T1 (en) * 2006-08-17 2013-01-31 University Of Chicago Treatment of inflammatory diseases
AU2007323557A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
CA2669104A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
JP2010510249A (en) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション Sphingosine = 1-tetralin analog having 1-phosphate agonist activity
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
PL2278960T5 (en) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective sip1 receptor agonist
CA2724592A1 (en) * 2008-05-20 2009-11-26 Kyorin Pharmaceutical Co., Ltd. Agent for maintenance of induced remission
JP2011525189A (en) * 2008-06-20 2011-09-15 ノバルティス アーゲー Pediatric composition for treating multiple sclerosis
WO2010020609A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
CN101973898B (en) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-p-octylphenethyl-2-aminopropylene glycol derivative and application thereof
CN105611917A (en) 2013-10-11 2016-05-25 帝国制药美国公司 Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
CN103992985A (en) * 2014-05-09 2014-08-20 上海大学 Application of D-erythro-Sphingosine in central nervous system
ES2769902B2 (en) * 2018-12-28 2020-12-04 Consejo Superior Investigacion Use of secoiridoids for the treatment of optic neuritis.
TW202116297A (en) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 Combination therapy methods, compositions and kits
TW202131914A (en) 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 New treatment regimen for the treatment of neurological diseases or conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19739693A1 (en) * 1997-09-04 1999-03-11 Schering Ag Synergistic treatment of multiple sclerosis and other neurodegenerative disorders
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654333A (en) * 1986-02-18 1987-03-31 Unimed, Inc. Treatment of multiple sclerosis
RU2079304C1 (en) * 1990-11-08 1997-05-20 Фудзисава Фармасьютикал Ко., Лтд. Pharmaceutical composition showing immunosuppressive and antimicrobial activities
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE69321823T2 (en) * 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-AMINO-1, 3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSIUM
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
EP1155011A1 (en) 1999-02-20 2001-11-21 AstraZeneca AB Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin s
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
JP2002537293A (en) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ Acetamide acetonitrile derivatives as inhibitors of cathepsin L and / or cathepsin S
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
ATE264863T1 (en) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-EPIRAPALOGUE
EP1212302A1 (en) 1999-09-16 2002-06-12 Axys Pharmaceuticals, Inc. Compounds and pharmaceutical compositions as cathepsin s inhibitors
CO5280088A1 (en) 2000-04-18 2003-05-30 Smithkline Beecham Corp PROTEASA INHIBITORS
CN1328387C (en) * 2000-07-13 2007-07-25 三共株式会社 Amino alcohol derivatives
JP2002289768A (en) * 2000-07-17 2002-10-04 Rohm Co Ltd Semiconductor device and its manufacturing method
EP1309591B1 (en) 2000-08-14 2007-01-24 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
EP1326848A1 (en) 2000-10-19 2003-07-16 Naeja Pharmaceutical Inc. Dihydropyrimidine derivatives as cysteine protease inhibitors
MXPA03005601A (en) 2000-12-22 2004-12-02 Axys Pharm Inc Novel compounds and compositions as cathepsin inhibitors.
CA2442178A1 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (en) 2001-04-20 2002-10-31 Sankyo Co Ltd Benzothiophene derivative
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
JP2005504078A (en) 2001-09-14 2005-02-10 アベンティス・ファーマスーティカルズ・インコーポレイテツド Novel compounds and compositions as cathepsin inhibitors
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (en) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk OSUPPRESSIVUM
CA2459825A1 (en) 2001-10-02 2003-04-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
CA2463770A1 (en) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
WO2003041649A2 (en) 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Cyanoalkylamino derivatives as protease inhibitors
MXPA04004450A (en) 2001-11-14 2004-08-11 Aventis Pharma Inc Oligopeptides and compositions containing them as cathepsin s inhibitors.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
DE19739693A1 (en) * 1997-09-04 1999-03-11 Schering Ag Synergistic treatment of multiple sclerosis and other neurodegenerative disorders
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRINKMANN V ET AL: "FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 14, no. 5, 19 July 2002 (2002-07-19), pages 569 - 575, XP004377409, ISSN: 0952-7915 *
BRINKMANN VOLKER ET AL: "The immune modulator FTY720 targets sphingosine 1-phosphate receptors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 24, 14 June 2002 (2002-06-14), pages 21453 - 21457, XP002264445, ISSN: 0021-9258 *
HOSHINO Y ET AL: "FTY720, a novel immunsuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models", TRANSPLANTATION PROCEEDINGS, vol. 31, no. 1-2, February 1999 (1999-02-01), XVIIth World Congress of the Transplantation Society;Montreal, Quebec, Canada; July 12-17, 1998, pages 1224 - 1226, XP002264446, ISSN: 0041-1345 *
MOSER HUGO W: "Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, vol. 54, no. 5, 1995, pages 740 - 745, XP009022840, ISSN: 0022-3069 *

Also Published As

Publication number Publication date
WO2004028521A2 (en) 2004-04-08
PL375053A1 (en) 2005-11-14
TW200406369A (en) 2004-05-01
AU2003266404B2 (en) 2007-08-09
AU2007231645B2 (en) 2010-12-16
NO334908B1 (en) 2014-07-07
MXPA05003254A (en) 2005-06-08
JP2010120962A (en) 2010-06-03
EP2255798B1 (en) 2014-12-24
NO20131569L (en) 2005-04-20
EP2255798A2 (en) 2010-12-01
EP2251007A3 (en) 2011-03-23
EP1575576A2 (en) 2005-09-21
CA2499622C (en) 2012-01-03
RU2009136626A (en) 2011-04-10
PL408347A1 (en) 2014-08-18
NZ564626A (en) 2009-08-28
CN1708293A (en) 2005-12-14
EP2251007A2 (en) 2010-11-17
US20090324542A1 (en) 2009-12-31
CA2499622A1 (en) 2004-04-08
AU2007231645A1 (en) 2007-11-15
TWI335311B (en) 2011-01-01
ZA200502032B (en) 2005-10-26
AU2003266404A1 (en) 2004-04-19
KR20050054958A (en) 2005-06-10
RU2012153692A (en) 2014-06-20
RU2478378C2 (en) 2013-04-10
KR101095807B1 (en) 2011-12-21
NO20051934L (en) 2005-04-20
AU2010246492A1 (en) 2010-12-23
CN102526079B (en) 2014-06-18
AU2010246492B2 (en) 2012-08-30
KR20080103117A (en) 2008-11-26
KR20090125226A (en) 2009-12-03
CN102526079A (en) 2012-07-04
CN101843897A (en) 2010-09-29
JP2006503924A (en) 2006-02-02
US20060046979A1 (en) 2006-03-02
RU2005112714A (en) 2006-01-27
CN101843897B (en) 2014-04-30
US20120225031A1 (en) 2012-09-06
TW201100359A (en) 2011-01-01
EP2255798A3 (en) 2011-03-23
RU2391094C2 (en) 2010-06-10
NZ538961A (en) 2008-02-29
BR0314760A (en) 2005-07-26
JP4509028B2 (en) 2010-07-21
US20140271541A1 (en) 2014-09-18
KR20110038188A (en) 2011-04-13
TWI376363B (en) 2012-11-11
KR101188943B1 (en) 2012-10-08

Similar Documents

Publication Publication Date Title
WO2004028521A3 (en) Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2004010987A3 (en) Use of s1p receptor agonists in heart diseases
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2006053160A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2005051308A3 (en) Methods of treating diseases and disorders by targeting multiple kinases
SG166115A1 (en) Pharmaceutical preparation containing meloxicam
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2007149283A3 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
MXPA05003253A (en) Novel pyrimidineamide derivatives and the use thereof.
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2003099202A3 (en) Beta-secretase inhibitors
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2004030618A3 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005009217A3 (en) Diagnosis of pre-cancerous conditions using pcdgf agents
WO2010008474A3 (en) Methods for treating multiple sclerosis using antisense oligonucleotides
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2001026639A3 (en) Pharmaceutical composition of ateglinide and another antidiabeticagent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003798176

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005/02032

Country of ref document: ZA

Ref document number: 200502032

Country of ref document: ZA

Ref document number: 2003266404

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 167519

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2499622

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2006046979

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500582

Country of ref document: PH

Ref document number: 538961

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/003254

Country of ref document: MX

Ref document number: 2005509665

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 375053

Country of ref document: PL

Ref document number: 1020057005033

Country of ref document: KR

Ref document number: 20038227088

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005112714

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10528688

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020057005033

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003798176

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10528688

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003266404

Country of ref document: AU